FDA removes clinical hold on Advaxis’ Axalimogene Filolisbac, Durvalumab combo trial

Advaxis, a biotech firm based in New Jersey, announced a significant regulatory update as the U.S. Food and Drug Administration (FDA) has lifted the clinical ... Read More